Key facts
- Pirouette Pharma’s last known valuation is $95.0M (Feb 2026).
- It has raised $22.9M across 2 recorded rounds; the latest was Seed Round ($1.1M) in Mar 2026.
- Notable investors include Y Combinator, Gaingels, Liquid 2 Ventures, Asymmetry Ventures, 515 Ventures — 20 tracked in total.
- Pirouette Pharma has filed 1 Form D with the SEC, most recently Apr 2025 ($2.4M sold to 1 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 20 names
- ·Watchlist + deal alerts for Pirouette Pharma
Funding rounds
2 roundsAbout Pirouette Pharma
Developer of automated injectors designed for the emergency treatment of severe allergic reactions. The company's injectors are portable and intuitive and address all the major pain points through a human-centered design that focuses on auto-injector places healthcare in the hands of the patient, where the improved patient experience is built on increased access, enabling healthcare industries to diversely apply drugs that require fixed-dose, single-use intramuscular or subcutaneous injections.
- Sector
- Healthcare
- HQ
- Portsmouth, NH, United States
- Founded
- 2017
- Employees
- 29
- Website
- pirouettepharma.com/
- Ownership
- Privately Held (backing)
Pirouette Pharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Pirouette Pharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Pirouette Pharma in its N-PORT filings yet. We sweep new filings monthly.